Samsung Biologics Co.,Ltd. (KRX:207940)
South Korea flag South Korea · Delayed Price · Currency is KRW
1,028,000
+2,000 (0.19%)
At close: May 28, 2025, 3:30 PM KST

Samsung Biologics Revenue

Samsung Biologics had revenue of 1.30T KRW in the quarter ending March 31, 2025, with 37.11% growth. This brings the company's revenue in the last twelve months to 4.90T, up 24.95% year-over-year. In the year 2024, Samsung Biologics had annual revenue of 4.55T with 23.08% growth.

Revenue (ttm)
4,898.69B
Revenue Growth
+24.95%
P/S Ratio
14.94
Revenue / Employee
1.03B
Employees
4,770
Market Cap
73.17T

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 20244,547.32B852.73B23.08%
Dec 31, 20233,694.59B693.29B23.10%
Dec 31, 20223,001.30B1,433.29B91.41%
Dec 31, 20211,568.01B403.23B34.62%
Dec 31, 20201,164.78B463.19B66.02%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Celltrion 3,662.23B
ALTEOGEN 151.65B
Yuhan 2,114.76B
SK Biopharmaceuticals 578.00B
HLB Co., Ltd. 74.64B
Peptron 3.15B
PharmaResearch 392.31B
LigaChem Biosciences 125.90B
Revenue Rankings